Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
MASLD and MASH can lead to liver fibrosis, cirrhosis and liver cancer.
However, only 24% of people with hepatocellular carcinoma received direct-acting antiviral therapy.
An increase in fatty liver disease could double liver cancer cases and nearly triple the need for transplants by 2050.
Hepatocellular carcinoma among people with HCV fell after the debut of direct-acting antivirals, but cases are rising for other groups.
In 2022, fatty liver disease accounted for nearly a quarter of all liver cancer cases on the transplant waiting list.
About 40% of people worldwide are not aware that viral hepatitis is a leading cause of liver cancer.
Men, people with obesity and people who smoke are more likely to develop NAFLD.
Human papillomavirus and hepatitis B vaccines lower the risk of developing cancer.
People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.
People treated with direct-acting antivirals had a lower risk for liver failure and liver cancer as well as much lower mortality.
Experts predict that more than a million people could die from liver cancer worldwide in 2040.
People who achieved SVR two or more years ago were less likely to develop hepatocellular carcinoma than those cured more recently.
People with hepatocellular carcinoma had improved survival after the advent of direct-acting antiviral therapy.
However, people with liver cirrhosis remain at risk and should continue screening even after being cured.
Second- and third-generation individuals in Los Angeles had a 35% and 61% higher risk, respectively, than those born in Mexico.
“I’m glad to go to bat for the One Liver to Love initiative to encourage others to be proactive,” says Latino legend Bernie Williams.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.